Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 330-341 , October 2001

Recent advances in radionuclide therapy

  • Suresh Srivastava

      Affiliations

    • Brookhaven National Laboratory, Medical Department, Upton, NY, USA
    • Albert Einstein College of Medicine, Bronx, NY, USA
    • Corresponding Author InformationAddress reprint requests to Suresh C. Srivastava, PhD, Brookhaven National Laboratory, Medical Department, Building 801, P.O. Box 5000, Upton, NY 11973-5000.
    • ,
  • Ekaterina Dadachova

      Affiliations

    • Brookhaven National Laboratory, Medical Department, Upton, NY, USA
    • Albert Einstein College of Medicine, Bronx, NY, USA

References 

  1. Volkert WA, Goeckler WF, Ehrhardt GJ, et al. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med. 1991;32:174–185
  2. Wheldon TE. Targeting radiation to tumors. Int J Radiat Biol. 1994;65:109–116
  3. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  4. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys. 1993;20:503–509
  5. Srivastava SC. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm. 1996;11:43–50
  6. Ercan MT, Caglar M. Therapeutic radiopharmaceuticals. Cur Pharm Design. 2000;6:1085–1121
  7. Srivastava SC. Therapeutic radionuclides: Making the right choice. In: Mather SJ editors. Current Directions in Radiopharmaceutical Research and Development. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996;p. 63–79
  8. Srivastava SC. Traditional and new isotopes for radioimmunotherapy. In: Riva P editors. Therapy of Malignancies With Radioconjugated Monoclonal Antibodies: Present Possibilities and Future Perspectives. Chur, Switzerland: Harwood Academic Publishers; 1999;p. 11–26
  9. In: Srivastava SC editors. Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York: Plenum Press; 1988;
  10. Larson S, Digvi C, Scott A, et al. Current status of radioimmunotherapy. Nucl Med Biol. 1994;21:785–792
  11. Milenic DE. Radioimmunotherapy: Designer molecules to potentiate effective therapy. Semin Radiat Oncol. 2000;10:139–155
  12. Saga T, Weinstein J, Jeong J, et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 1994;54:2160–2165
  13. Hu S-Z, Shively L, Raubitschek A, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996;56:3055–3061
  14. Wu A, Yazaki P. Designer genes: Recombinant antibody fragments for biological imaging. Quart J Nucl Med. 1999;43:268–283
  15. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol. 2000;10:73–93
  16. DeNardo GL, DeNardo SJ, O'Donnell RT, et al. Are radiometallabeled antibodies better than iodine-131-labeled antibodies: Comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma. 2000;1:118–126
  17. DeNardo GL, DeNardo SJ, Kukis DL, et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res. 1998;18:2779–2788
  18. DeNardo SJ, DeNardo GL, Kukis DL, et al. Cu-67-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med. 1999;40:302–310
  19. (suppl) Vriesendorp HM, Morton JD, Quadri SM, et al. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res. 1995;55:5888–5892
  20. Scheinberg DA. Antibody-mediated therapy of minimal residual leukemia: Use of humanized monoclonal antibodies and targeted alpha particles. In: Proceedings of the European Biological Society 4th International Symposium on the Biological Therapy of Cancer. Munich, Germany. 1997;
  21. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213-Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935–1946
  22. Jacobs AJ, Fer M, Su FM, et al. A phase I clinical trial of 186-rhenium-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol. 1993;82:586–593
  23. Alvarez RD, Partridge EE, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177-Lu-CC49: A phase I/II study. Gynecol Oncol. 1997;65:94–101
  24. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med. 1996;37:1491–1496
  25. Riva P, Arisata A, Sturiale C, et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131-I-labeled antitenascin monoclonal antibody BC-2. Int J Cancer. 1992;51:7–13
  26. Westlin JE, Snook D, Nilsson S, et al. Intravenous and intratumoral therapy of patients with malignant gliomas with 90-yttrium-labeled monoclonal antibody MUC 2–63. In: Epenetos A editors. Monoclonal Antibodies 2: Applications in Clinical Oncology. London: Chapman & Hall; 1993;p. 17–25
  27. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high-grade glioma with yttrium-90 biotin. Eur J Nucl Med. 1999;26:348–357
  28. Cutler CS, Lewis JS, Anderson CJ. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Ad Drug Deliv Rev. 1999;37:189–211
  29. de Jong M, Bernard HF, de Bruin E, et al. Internalization of radiolabeled [DTPA]-octreotide and [DOTA, Tyr3] octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 1998;19:283–288
  30. Janson ET, Westlin JE, Öhrvall U, et al. Nuclear localization of In-111 after intravenous injection of [In-111-D-Phe1]-Octreotide in patients with neuroendocrine tumors. J Nucl Med. 2000;41:1514–1518
  31. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–1713
  32. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phel-Tyr3-Octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm. 1999;14:477–483
  33. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med. 1999;26:1439–1447
  34. Popma JJ, Califf RM, Topol E. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426–1436
  35. Weinberger J. Intracoronary radiation using radioisotope solution-filled balloons. Herz. 1998;23:366–372
  36. Hoher M, Wohrle J, Wohlfrom M, et al. Intracoronary beta-irradiation with a liquid Re-188-filled balloon: Six-month results from a clinical safety and feasibility study. Circulation. 2000;101:2355–2360
  37. Kotzerke J, Hanke H, Hoher M. Endovascular brachytherapy for the prevention of restenosis after angioplasty. Eur J Nucl Med. 2000;27:223–236
  38. Knapp FF. Rhenium-188: A generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm. 1998;13:337–349
  39. Deutsch E, Broadack J, Deutsch K. Radiation synovectomy revisited. Eur J Nucl Med. 1993;20:1113
  40. Chinol M, Vallabhajousula S, Goldsmith S, et al. Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: Potential radiopharmaceutical for radiation synovectomy. J Nucl Med. 1993;34:1536
  41. Pecher C. Biological investigations with radioactive calcium and strontium: Preliminary report on the use of radioactive strontium in the treatment of bone cancer. University of California Publications in Pharmacology. 1942;11:117–149
  42. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. AJR Am J Roentgenol. 1950;64:559–575
  43. Firusian N, Mellin P, Schmidt CG. Results of Sr-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: A preliminary report. J Urol. 1976;116:764–768
  44. Robinson RG. Radionuclides for the alleviation of bone pain in advanced malignancy. Clin Oncol. 1986;5:39–49
  45. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam therapy radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33–40
  46. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27:954–958
  47. Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium-89. Nucl Med Biol. 1987;14:219–222
  48. Katin MJ, Salenius SA, Blitzer PH, et al. Hematologic effects of Sr-89 treatment for metastases to bone. Proc Amer Soc Clin Oncol. 1993;3:12
  49. Kaplan E, Fels IG, Kotlowski BR. Therapy of carcinoma of the prostate metastatic to bone with P-32-labeled condensed phosphate. J Nucl Med. 1960;1:1–13
  50. Edland RW. Testosterone potentiated radiophosphorus therapy of osseous metastases in prostate cancer. AJR Am J Roentgenol. 1974;120:678–683
  51. Maxfield JR, Maxfield JGS, Maxfield WS. The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate. South Med J. 1958;51:320–328
  52. Nair N. Relative efficacy of P-32 and Sr-82 in palliation in skeletal metastases. J Nucl Med. 1999;40:256–261
  53. Turner JH, Claringbold PG. A phase II study of painful multifocal skeletal metastases with single- and repeated-dose samarium- 153 ethylenediaminetetra methylene phosphonate. Eur J Cancer. 1991;27:1084–1086
  54. Farhangi M, Holmes RA, Volkert WA, et al. Samarium-153 EDTMP: Pharmacokinetics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451–1458
  55. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMA in bone metastases of hormone refractory prostate cancer: A phase I/II trial. J Nucl Med. 1993;34:1839–1844
  56. Resche I, Chatal J-F, Pecking A, et al. A dose-controlled study of Sm-153-ethylenediaminetetra methylene phsophonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583–1591
  57. Maxon HR, Schroder LE, Thomas SR. Re-186(Sn)HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology. 1990;176:155–159
  58. de Klerk JMH, Dijk AV, Schip BH, et al. Pharmacokinetics of rhenium- 186 after administration of rhenium- 186-HEDP to patients with bone metastases. J Nucl Med. 1992;33:646–651
  59. Kolesnikov-Gauthier H, Carpentier P, Depreux P, et al. Evaluation of toxicity and efficacy of Re- 186-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med. 2000;41:1689–1694
  60. Atkins HL, Mausner LF, Srivastava SC, et al. Human biodistribution of Sn- 117m(4+)DTPA: A new agent for palliative treatment of painful osseous metastases. Radiology. 1993;186:279–283
  61. Atkins HL, Mausner LF, Srivastava SC, et al. Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: A pilot study. J Nucl Med. 1995;36:725–729
  62. Krishnamurthy GT, Swailem FM, Srivastava SC, et al. Tin-117m(4+)DTPA pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med. 1997;38:230–237
  63. Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with tin-117m stannic DTPA: A phase I/II clinical study. Clin Cancer Res. 1998;4:61–68
  64. Srivastava SC, Meinken GE, Mausner LF, et al. Nuclear, chemical, and mechanistic consideration in the use of Sn-117m(4+)-DTPA relative to Re-186-HEDP and other agents for bone pain therapy. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Padova: SG Editoriali; 1995;p. 287–292
  65. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-II trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine-resistant metastatic prostate cancer. Int J Radiat Oncol Biol Physics. 1993;25:805–813
  66. Carretta RF, Weiland FL, Vande Streek PR, et al. Five years of clinical experience with Sr-89. Eur J Nucl Med. 1994;21:S44
  67. de Klerk JMH, van het Schip AD, Zonnenberg BA, et al. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med. 1996;37:244–249
  68. (abstr) Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Long-term analysis of clincial data from patients treated with Sn-117m DTPA for metastatic bone pain. J Nucl Med. 1999;40:65P
  69. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989;9:271–281
  70. Fossa SD, Paus E, Lochoff M, et al. Strontium-89 in bone metastases from hormone resistant-prostate cancer: Palliation effect and biochemical changes. Br J Cancer. 1992;66:177–180
  71. Bishayee A, Rao DV, Srivastava SC, et al. Marrow-sparing effects of Sn-117m(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med. 2000;41:2043–2050
  72. Silberstein EB. Availability of radioisotopes produced in North America. J Nucl Med. 2000;41:10N–13N
  73. Blower PJ. Extending the life of a 99Tcm generator: A simple and convenient method for concentrating generator eluate for clinical use. Nucl Med Commun. 1993;14:995–997
  74. Wu C, Brechbiel MW, Gansow OA. An improved generator for the production of Bi-213 from Ac-225. Radiochem Acta. 1997;79:141–144
  75. McDevitt MR, Finn RD, Sgouros G, et al. An 225Ac/213Bi generator system for therapeutic clinical applications: Construction and operation. Appl Radiat Isot. 1999;50:895–904
  76. Koch L, Apostolidis C, Molinet R, et al. Bi-213 conjugated to MAb for alpha-immunotherapy. Abstr Soc Meeting. 1998;1:S215
  77. Srivastava SC, Mausner LF. Production and supply of radionuclides with high-energy particle accelerators: Current status and future directions. In: Proceedings of the 21st Japan Conference on Radiation and Radioisotopes. Japan Atomic Industrial Forum, B-550. February 2–4, 1994;p. 1–11
  78. Srivastava SC. Is there life after technetium: What is the potential for developing new broad-based radionuclides?. Semin Nucl Med. 1996;26:119–131
  79. Mausner LF, Srivastava SC. Current status and future directions of production of radioisotopes with high-energy accelerators. In: Proceedings of the Third International Topical Meeting on Nuclear Applications of Accelerator Technology. American Nuclear Society, Long Beach, CA. November 14–18, 1999;p. 13–19
  80. Vera-Ruiz H. In: Cyclotron Facilities With Radionuclide Production Programs in Member States. Vienna, Austria: International Atomic Energy Agency; 1983;
  81. US Department of Energy, Health and Environmental Research Advisory Committee, Subcommittee on Nuclear Medicine, 1989
  82. Holmes RA. In: National Biomedical Tracer Facilities: Planning and Feasibility Study. New York, New York: US Department of Energy, Society of Nuclear Medicine; 1991;
  83. Adelstein SJ. In: Isotopes for Medicine and the Life Sciences. Washington, DC: National Academy Press; 1995;
  84. Choppin GR, Welch MJ. Training requirements for chemists in nuclear medicine, nuclear industry, and related areas: Report of a workshop. Washington, DC: National Academy Press; 1988;
  85. Yates W. Future challenges in nuclear science education. J Radioanalytical Nucl Chem. 1993;171:15–21
  86. Isaacs T. Nuclear education and training: Cause for concern?. Nuclear Energy Agency, Organization for Economic Cooperation and Development; 2000;
  87. Mausner LF, Mirzadeh S, Maher R, et al. Production of high specific-activity 117mSn with the Szilard-Chalmers process. J Labelled Compds Radiopharm. 1989;16:177–178
  88. Mausner LF, Kolsky KL, Joshi V, et al. Radionuclide development at BNL for nuclear medicine therapy. Appl Radiat Isot. 1998;49:285–294
  89. Kolsky KL, Joshi V, Mausner LF, et al. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl Radiat Isot. 1998;49:1541–1549
  90. Mausner LF, Kolsky KL, Joshi V, et al. Scandium-47, a replacement for Cu-67 in nuclear medicine therapy with β/γ emitters. In: Stevenson NR editors. Proceedings of the 3rd International Conference on Isotopes: Isotope Production and Applications in the 21st Century. 1999, Vancouver, Canada, World Scientific. 1999;p. 43–45
  91. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52:237–266
  92. Mousa SA. In: Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications. Georgetown, TX: Landes Bioscience; 2000;
  93. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15–R24
  94. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377–380
  95. Blok D, Feitsma RI, Vermeij P, et al. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med. 1999;26:1511–1519
  96. Mariani G, Bodeli L, Adelstein SJ, et al. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med. 2000;41:1519–1521
  97. Lin WY, Tsai SC, Hsieh BT, et al. Evaluation of three rhenium-188 candidates for intravascular radiation therapy with liquid-filled balloons to prevent restenosis. J Nucl Cardiol. 2000;7:37–42
  98. Kilbane MT, Ajjan RA, Weetman AP, et al. Tissue iodine content and serum-mediated I-125 uptake-blocking activity in breast cancer. J Clin Endocrinol Metab. 2000;85:1245–1250
  99. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during location and in breast cancer. Nature Med. 2000;6:871–878
  100. Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta. 1993;1154:65–82
  101. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 2000;60:3484–3492

1 Supported by the United States Department of Energy, NE/Office of Isotopes for Medicine and Science, under Contract No. DE-AC02-76CH00016 at Brookhaven National Laboratory, and by Albert Einstein College of Medicine Grant #9-526-9593.

PII: S0001-2998(01)80012-X

doi: 10.1053/snuc.2001.27043

Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 330-341 , October 2001

Article Tools